# US 2021/0268025 A1 · Method for Culturing Natural Killer Cells Using T Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268025 A1
- Document ID: US20210268025A1
- Status: Published application
- Kind: A1
- Application number: 17/220,865
- Filed: 2021-04-01
- Published: 2021-09-02
- Earliest claimed: 2014-11-26
- Assignees: Green Cross Lab Cell Corporation; Mogam Institute for Biomedical Research
- Applicants: Green Cross Lab Cell Corporation; Mogam Institute for Biomedical Research
- Inventors: Bo Kyung Min; Hana Choi; Yu Kyeong Hwang
- Web page: https://patentgrep.com/patent/US20210268025A1

## CPC

- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- C12N 5/0634: {Cells from the blood or the immune system}
- C12N 5/0636: {T lymphocytes}
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K 2239/47: Brain; Nervous system
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/53: Liver
- A61K 2239/59: Reproductive system, e.g. uterus, ovaries, cervix or testes
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2502/1114: T cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method for producing natural killer cells using T cells, and more particularly, to a method for producing natural killer cells, which comprises culturing seed cells using CD4(+) T cells as feeder cells. The method for producing natural killer cells using T cells according to the present invention is a method capable of producing natural killer cells by selectively proliferating only natural killer cells from a small amount of seed cells while maintaining the high killing activity of the natural killer cells. The method of the present invention can produce a large amount of natural killer cells that can be frozen, and thus is useful for commercialization of cell therapeutic agents.

## Claims

### Claim at position 1

1-23. (canceled)

### Claim 24

A method for producing a population of natural killer cells, the method comprising:
(a) providing seed cells comprising natural killer cells; and
(b) expanding the seed cells by culturing with a first plurality of inactivated CD4(+) T cells to produce expanded seed cells,
thereby producing the population of natural killer cells.

### Claim 25 (depends on 24)

A natural killer cell produced by the method of claim 24.

### Claim 26

A method for preventing or treating cancer or infectious disease, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of a population of natural killer cells produced by the method comprising:
(a) providing seed cells comprising natural killer cells;
(b) expanding the seed cells by culturing with a first plurality of inactivated CD4(+) T cells to produce expanded seed cells,
thereby producing the population of natural killer cells.

### Claim 27 (depends on 26)

The method of claim 26, wherein the seed cells of step (a) are CD3(+)-depleted seed cells.

### Claim 28 (depends on 26)

The method of claim 26, wherein the seed cells provided in step (a) have not been expanded ex vivo or in vitro.

### Claim 29 (depends on 26)

The method of claim 26, wherein the seed cells provided in step (a) are selected from peripheral blood cells, peripheral blood leukocytes, and PBMCs (peripheral blood mononuclear cells).

### Claim 30 (depends on 26)

The method of claim 26, wherein the seed cells provided in step (a) are selected from enriched natural killer cells and isolated natural killer cells.

### Claim 31 (depends on 26)

The method of claim 26, wherein the CD4(+) T cell(s) are CD4(+) T cell(s) isolated ex vivo, CD4(+) T cell(s) expansion-cultured ex vivo, or a CD4(+) T cell line.

### Claim 32 (depends on 31)

The method of claim 31, wherein the CD4(+) T cell line is HuT78.

### Claim 33 (depends on 26)

The method of claim 26, wherein the culturing is carried out in a medium comprising a T-cell stimulating antibody and an interleukin protein.

### Claim 34 (depends on 33)

The method of claim 33, wherein the T-cell stimulating antibody is OKT3, UCHT1, HT3a, or a combination thereof.

### Claim 35 (depends on 34)

The method of claim 34, wherein the T-cell stimulating antibody is OKT3.

### Claim 36 (depends on 33)

The method of claim 33, wherein the interleukin protein is IL-2, IL-12, IL-15, IL18, IL21, or a combination thereof.

### Claim 37 (depends on 36)

The method of claim 36, wherein the interleukin protein is IL-2.

### Claim 38 (depends on 26)

The method of claim 26, wherein the culturing is carried out for 5-60 days.

### Claim 39 (depends on 26)

The method of claim 26, further comprising:
(c) culturing the expanded seed cell(s) produced in step (b) with a second plurality of inactivated CD4(+) T cell(s).

### Claim 40 (depends on 26)

The method of claim 26, wherein the activated natural killer cells are administered as part of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

### Claim 41 (depends on 26)

The method of claim 26, wherein the cancer is selected from blood cancer, lymphoma, liver cancer, brain cancer, retinoblastoma, neuroblastoma, and ovarian cancer.

### Claim 42

A method for preventing or treating cancer or infectious disease, the method comprising:
administering to a subject in need thereof a therapeutically effective amount of a population of natural killer cells produced by the method comprising:
(a) providing seed cells comprising natural killer cells, wherein the seed cells are depleted of CD3(+) cells, and wherein the seed cells have not been expanded ex vivo or in vitro;
(b) expanding the seed cells of step (a) by culturing with a first plurality of inactivated CD4(+) T cells to produce expanded seed cells; and
(c) culturing the expanded seed cell(s) with a second plurality of inactivated CD4(+) T cell(s),
thereby producing the population of natural killer cells.

### Claim 43 (depends on 41)

The method of claim 41, wherein the population of natural killer cells is administered as part of a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
